KALYDECO®
http://www.cysticfibrosis.ca/wp-content/themes/Cystic-Fibrosis-Canada/img/FB_Share_Image.jpg
LETTER OF INTENT FOR KALYDECO® SIGNED BY VERTEX AND THE PCPA PROVINCES Posted by Ken Chan, Vice President, Advoca…
DONATECLOSE
GENERAL DONATIONS
MONTHLY
IN HONOUR
IN MEMORY
Advocacy
Influencing health policy and government decision-making
in order to enhance the quality of life for CF patients

KALYDECO®

LETTER OF INTENT FOR KALYDECO® SIGNED BY VERTEX AND THE PCPA PROVINCES

Posted by Ken Chan, Vice President, Advocacy, Research and Healthcare on June 16, 2014 at 5:15 pm EDT

We are pleased to announce that a letter of intent has been entered into between the participating PCPA jurisdictions (Quebec excluded) on a pricing agreement for Kalydeco. A letter of intent typically sets out the standard terms for health ministries and Vertex when considering provincial coverage for Kalydeco. In terms of next steps, each provincial health ministry will consider how Kalydeco will be funded in accordance with its own drug reimbursement framework. Over the coming weeks, we will be updating patients and families on developments in each province.

We want to thank all our advocates especially those patients and families personally impacted by Kalydeco for their tenacity and courage in the fight for Kalydeco.

About KALYDECO®

KALYDECO® (ivacaftor) is a prescription medicine for the treatment of cystic fibrosis in patients ages six and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene. In Canada, the number of patients with this mutation is about 100. Kalydeco, a pill taken twice a day with fat-containing food, helps the protein made by the CFTR gene function better and, as a result, improves lung function and other aspects of cystic fibrosis such as increasing weight.

On November 26, 2012, Health Canada approved Kalydeco for use in Canada. On March 26, 2012, it was announced that the Canadian Drug Expert Committee recommends that Kalydeco be listed on the formulary listing of publicly funded drug plans for the treatment of cystic fibrosis in patients age six and older who have the G551D mutation in the CFTR. Today, only a handful of CF patients in Canada who need Kalydeco have access through private insurance. Quebec has its own drug review process through the Institut national d’excellence en santé et en services sociaux (INESSS).

Read our blog to learn more about Cystic Fibrosis Canada’s advocacy efforts on Kalydeco or look through Background Documents.

Kalydecare logo

kalydeCARE™ is a Patient Assistance Program for patients who have been have been prescribed Kalydeco™ by their health care provider. For more information please call: 1-855-CARE-571 (1-855-227-3571).

SHARE THIS PAGE